hypertriglyceridemia

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced new preclinical data demonstrating the delivery capabilities of its GalNAc conjugate technology in its hypercholesterolemia and hypertriglyceridemia programs.

The researchers identified an accumulation of rare variants in four genes identified by GWAS. They now plan to sequence more candidate genes using Sanger sequencing and, eventually, next-generation sequencing.

Using genome-wide association and targeted re-sequencing studies, a Canadian-led research team has uncovered common and rare genetic variants in four genes that are over-represented in individuals with extremely high blood triglyceride levels.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.